A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response

The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61–80 years of age with newly diagnosed CD20(+) diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ≥2). Patients receive standard chemotherapy (...

Descripción completa

Detalles Bibliográficos
Autores principales: Denker, Sophy, Bittner, Aitomi, Na, Il-Kang, Kase, Julia, Frick, Mareike, Anagnostopoulos, Ioannis, Hummel, Michael, Schmitt, Clemens A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2019
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939221/
https://www.ncbi.nlm.nih.gov/pubmed/31903182
http://dx.doi.org/10.2217/ijh-2019-0010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939221/
https://www.ncbi.nlm.nih.gov/pubmed/31903182
http://dx.doi.org/10.2217/ijh-2019-0010

Ejemplares similares